에 대한 최신 뉴스 Vaxcyte (NASDAQ:PCVX) 주식

VAXCYTE INC

Vaxcyte

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

Xpeng g6 SUV

Large Cap

News

Movers

ABBV

CACI

LDOS

MNDY

MPWR

MRNA

NVDA

PCVX

SMCI

XPEV

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 모놀리식 파워 시스템즈(NASDAQ:MPWR)의 주식은 24.68% 하락했다. 이는 엣지워터 리서치(Edgewater Research)의 분석 보고서에 따라 모놀리식의 엔비디아(NASDAQ:NVDA) 블랙웰(Blackwell) GPU에 대한 할당이 전력 관리 IC의 성능 문제로 위험에 처해 있다고 밝힌 후 발생한 일이다.

슈퍼 마이크로, 모더나 및 샤오펑은 지난주 최악의 성과를 보인 10개 대형주 중 일부 (11월 11일-15일)

Vaxcyte Inc

Rosenblatt analyst Mike Genovese maintains Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) with a Buy and raises the price target from $18 to $20.

Price Target

Analyst Ratings

EXTR

Rosenblatt Maintains Buy on Extreme Networks, Raises Price Target to $20

&nbsp;
Two months ago I gave Iran a 60 day ultimatum to "make a deal." They should have done it! Today is day 61. I told them what to do, but they just couldn't get there. Now they have, perhaps, a second chance!
&nbsp;
&nbsp;

Macro Economic Events

Global

Economics

iShares MSCI Israel Capped Investable Market Index Fund

President Trump Posts On Truth Social: 'Two months ago I gave Iran a 60 day ultimatum to "make a deal." They should have done it! Today is day 61. I told them what to do, but they just couldn't get there. Now they have, perhaps, a second chance!'

Barrington Research analyst Gary Prestopino maintains PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) with a Outperform and maintains $15 price target.

AIOT

Barrington Research Maintains Outperform on PowerFleet, Maintains $15 Price Target

Texas is the second‑most populous state2 in the U.S. and recorded over 323,000 home sales in 2024, with a median sale price of $347,000, representing more than $112 billion in residential transaction value3. This expansion into Texas positions reAlpha to reach millions of prospective homebuyers through a tech-enabled, streamlined platform that delivers real savings at closing, including in high-volume markets such as Dallas-Fort Worth, San Antonio, Houston, and Austin.
 &nbsp;

AIRE

reAlpha Tech Enters Texas Market With Launch Of AI-Driven Real Estate Brokerage Services

<a href="https://www.globenewswire.com/Tracker?data=sRJiU6AhBwRs7N2q0k9SUJED5c2NDl4SjhSsHUwYHRP4meEtNPhrehANOUDTP0kRW6urx4bwssPhRWmHGPipsA==">Altimmune, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association's (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD).
Details for the oral presentation are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Session Title:</td>
<td>Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies – Take 1</td>
</tr>
<tr>
<td>Session Date/Time:</td>
<td>Saturday, June 21, 2025, 4:30 PM - 6:00 PM CDT</td>
</tr>
<tr>
<td>Presentation Title:</td>
<td>Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight</td>
</tr>
<tr>
<td>Presenter:</td>
<td>John J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Saturday, June 21, 2025 at 5:45 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
Details of the poster presentations are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment (poster #749-P)</td>
</tr>
<tr>
<td>Presenter:</td>
<td>Shaheen Tomah, M.D., Director, Clinical Development, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Sunday, June 22, 2025, 12:30 PM - 1:30 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Non-invasive Tests of Central Adiposity Correlate with Reductions in MRI-measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide (poster #748-P)</td>
</tr>
<tr>
<td>Presenter:</td>
<td>Shaheen Tomah, M.D., Director, Clinical Development, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Sunday, June 22, 2025, 12:30 PM - 1:30 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model (poster #778-P)</td>
</tr>
<tr>
<td>Presenter:</td>
<td>John J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Sunday, June 22, 2025, 12:30PM - 1:30 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Altimmune to Present Data on Obesity and Liver Drug Pemvidutide at Upcoming Diabetes Conference

Phillips Edison &amp; Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PECO#NASDAQ">PECO</a>) ("PECO" or the "Company"), one of the nation's largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, today announced that its operating partnership, Phillips Edison Grocery Center Operating Partnership I, L.P. (the "Operating Partnership"), has priced a public offering of $350 million aggregate principal amount of 5.250% senior unsecured notes due 2032 (the "Notes"). The Notes were priced at 99.832% of the principal amount and will mature on August 15, 2032. The offering is expected to settle on June 17, 2025, subject to the satisfaction of customary closing conditions. The notes will be fully and unconditionally guaranteed by PECO.
The Operating Partnership intends to use the net proceeds from the offering for general corporate purposes, including to repay borrowings under its revolving credit facility, to repay its term loans and other outstanding indebtedness, to acquire additional properties, for capital expenditures, expansion and working capital, to redevelop and/or improve properties and for other general corporate purposes. Pending application of the net proceeds from the offering for the foregoing purposes, such proceeds may initially be invested in short-term securities.

PECO

Phillips Edison's Operating Partnership Prices Public Offering Of $350M Aggregate Principal Amount Of 5.250% Senior Unsecured Notes Due 2032

ASTS

AST SpaceMobile Settles Term Sheet Facilitating Long-Term Access To Up To 45 MHz Of Premium Lower Mid-Band Spectrum In North America For Direct-to-Device Satellite Applications

Sensei Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will implement a 1-for-20 reverse stock split of its issued and outstanding shares of common stock ("Reverse Stock Split"), effective at&nbsp;5:00 p.m. Eastern Time&nbsp;on&nbsp;June 16, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on&nbsp;May 21, 2025, with the final ratio subsequently determined by the Company's Board of Directors. The reverse stock split is intended to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on Tuesday,&nbsp;June 17, 2025&nbsp;under the Company's existing trading symbol "SNSE" with the new CUSIP number 81728A207.

Stock Split

SNSE

Sensei Biotherapeutics To Implement 1-For-20 Reverse Stock Split Of Issued And Outstanding Shares, Effective June 16, 2025

Senmiao Technology Limited ("Senmiao" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/AIHS#NASDAQ">AIHS</a>), a financing and servicing company focused on the online ride-hailing industry in China, today announced that it has signed a strategic cooperation agreement (the "Agreement") with <a href="https://www.globenewswire.com/Tracker?data=JVw778hMIeG3PerOje-sevKZsnS-KaGXq6E6ME5yrktKIa1u6LtMSnlJUCJ0TEFm5fbR1E2ej7GGHMvmvfdJHkfacsuagMlltv-51zSUR8O0BAZ0bWw-g_b2pnrSZrvpSTR-GQsgbBMEPtYd3q0-aA==">Changsha Yipeng Information Technology Co., Ltd</a>. ("Changsha Yipeng") to jointly develop an AI-backed data management system aiming to improve efficiency of online ride-hailing management platforms.
Changsha Yipeng has over a decade of experience in developing integrated AI-based information systems, big data, and cloud platforms for government and private entities in China, across a variety of sectors.
Pursuant to the Agreement, Changsha Yipeng will utilize Senmiao's data (related to drivers, vehicles and riders) from its historical operating information, to develop an AI-backed data management system to facilitate the collection and analysis of data and ultimately provide online ride-hailing service providers with efficient and safe ways to operate their service vehicles. Along with the development of the project,, both parties will jointly seek necessary financing for its full development and deployment.

AIHS

Senmiao Teams Up With AI Firm to Boost Ride-Hailing Efficiency in China With Smart Data Platform

PROS Holdings Reaffirms Q2 Outlook Of Total Revenues Of $87M-$88M Vs. $89.24M Estimate, And Adjusted EPS Of $0.04-$0.06 Vs. $0.12 Estimate

Wells Fargo analyst Finian O'Shea initiates coverage on Blue Owl Technology Finance Corp. Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTF#NYSE">OTF</a>) with a Equal-Weight rating and announces Price Target of $15.

Initiation

Wells Fargo Initiates Coverage On Blue Owl Technology Finance Corp. Common Stock with Equal-Weight Rating, Announces Price Target of $15

The Federal Reserve is widely expected to maintain its benchmark interest rate in the 4.25%-4.50% range at next week&#8217;s policy meeting, as policymakers weigh recent soft inflation <a href="https://www.benzinga.com/news/politics/25/06/45913481/trump-rips-jerome-powell-over-rates-but-supreme-court-shields-fed-from-firing">data against ongoing uncertainty </a>from President Donald Trump&#8216;s trade policies and demands for aggressive rate cuts.
What Happened: The Federal Reserve will likely keep rates unchanged at its June 17-18 meeting despite recent inflation readings showing consumer and producer prices both increased less than expected in May, reported Reuters. Fed Chair Jerome Powell has indicated the central bank will maintain a &#8220;wait-and-see&#8221; approach amid unresolved trade and budget issues that could impact both inflation and economic growth.
Gregory Daco, chief economist at EY-Parthenon, said, &#8220;Recent Fed commentary has reinforced a wait-and-see approach, with officials signaling little urgency to adjust policy amid increased uncertainty around the economic outlook.&#8221;
Trump has <a href="https://www.benzinga.com/news/politics/25/06/45913481/trump-rips-jerome-powell-over-rates-but-supreme-court-shields-fed-from-firing">demanded the central bank</a> immediately cut its benchmark overnight interest rate by a full percentage point, calling Fed Chair Powell &#8220;one numbskull&#8221; for maintaining current policy. At a White House meeting last month, Powell told the president he would not allow politics to influence monetary policy decisions.
The Fed&#8217;s policy rate has remained in the current range since December, when officials expected to begin a steady series of rate reductions. However, Trump&#8217;s trade policies raised risks of higher inflation and slower growth, complicating the central bank&#8217;s dual mandate of price stability and maximum employment.
See Also: <a href="https://www.benzinga.com/news/politics/25/06/45922022/trump-issues-stark-warning-to-iran-to-make-a-deal-after-israels-strikes-on-nuclear-sites-just-do-it-before-its-too-late">Trump Issues Stark Warning To Iran To &#8216;Make A Deal&#8217; After Israel&#8217;s Strikes On Nuclear Sites: &#8216;Just Do It Before It&#8217;s Too Late&#8217;</a>
Why It Matters: Market participants currently price in expectations for possible rate cuts this year, with recent data showing year-over-year inflation measured by the Fed&#8217;s preferred Personal Consumption Expenditures Price Index running close to the 2% target over the past three months. The unemployment rate has held steady at 4.2% for three consecutive months.
President Trump on Thursday escalated his criticism of Powell, blaming the Federal Reserve chief&#8217;s rate stance for higher <a href="https://www.benzinga.com/topic/national-debt" target="_blank" rel="noreferrer noopener">U.S. debt costs.</a> &#8220;We can&#8217;t get this guy to do it," he said. "And the fake news is saying, ‘Oh if you fired him it would be so bad.' I don&#8217;t know why it would be so bad, but I&#8217;m not going to fire him.&#8221;
The Supreme Court recently <a href="https://www.benzinga.com/25/05/45579414/supreme-court-says-trump-cant-fire-jerome-powellthe-fed-a-uniquely-structured-quasi-private-entity">upheld the Federal Reserve&#8217;s independence</a> from presidential interference, describing it as a &#8220;uniquely structured, quasi-private entity&#8221; that cannot be dismissed without cause. This legal protection shields Powell, whose term ends in May 2026, from Trump&#8217;s repeated threats of removal for not cutting rates aggressively enough.
Minneapolis Fed President Neel Kashkari warned that tariff negotiations &#8220;may take months or years&#8221; to conclude, with potential for &#8220;tit-for-tat tariff increases&#8221; from trading partners. Goldman Sachs analysts lowered recession odds to around 30% but maintained expectations that higher inflation numbers over the summer could sideline rate cuts until December. Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/topics/25/06/45922274/world-economic-forum-says-gender-equality-is-123-years-away-un-projects-7-trillion-boost-to-global-economy-if-gap-closes">World Economic Forum Says Gender Equality Is 123 Years Away: UN Projects $7 Trillion Boost To Global Economy If Gap Closes</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: Poetra.RH On Shutterstock

Fed Likely To Hold Interest Rates Steady In June Policy Meeting Despite Trump Slamming Jerome Powell, Saying 'We Can't Get This Guy To Do It'

<a href="https://x.com/GMA/status/1933483846558773341" title="https://x.com/GMA/status/1933483846558773341">https://x.com/GMA/status/1933483846558773341</a>

President Trump, On Iran Strikes, Tells ABC "there's more to come"

RH: 20% &#x7C; <a href="https://www.benzinga.com//node/45914233">RH shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and announced it is maintaining its current FY25 guidance despite tariff and macroeconomic event uncertainty.</a>
&nbsp;
ADBE: -3% &#x7C; <a href="https://www.benzinga.com//node/45916910">ADBE stock has given up its prior gain. Adobe shares were trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance.</a>
&nbsp;
UAL: -5% &#x7C; <a href="https://www.benzinga.com//node/45921817">Shares of airline stocks are trading lower following Israel's strikes on Iran, which have raised fuel prices and could cloud the travel demand outlook. The recent crash of an Air India flight could also be pressuring the sector.</a>

Trading Ideas

ADBE

Market-Moving News for June 13th

Wells Fargo analyst Michael Turrin upgrades Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) from Underweight to Equal-Weight and raises the price target from $67 to $80.

Upgrades

DOCU

Wells Fargo Upgrades Docusign to Equal-Weight, Raises Price Target to $80

Wells Fargo analyst Michael Berg upgrades Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) from Equal-Weight to Overweight and raises the price target from $32 to $40.

KVYO

Wells Fargo Upgrades Klaviyo to Overweight, Raises Price Target to $40

Wells Fargo analyst Michael Turrin downgrades ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTM#NASDAQ">GTM</a>) from Equal-Weight to Underweight and lowers the price target from $10 to $9.

Downgrades

Wells Fargo Downgrades ZoomInfo Technologies to Underweight, Lowers Price Target to $9

Rising Middle East tensions and President Donald Trump&#8217;s threats to Iran are flaring uncertainty in the global and U.S. markets. As a result, money is flowing from equities to safe-haven assets like gold.
Also, the crude oil price is soaring as rising conflict threatens OPEC crude supply.
<h2 class="wp-block-heading">Asia Markets Today</h2>
On Friday, Japan&#8217;s Nikkei 225 closed 0.92% lower at 37,821.50, led by losses in the Paper &amp; Pulp, Transport and Communication sectors.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Australia&#8217;s S&amp;P/ASX 200 was down 0.21% at 8,547.40, led by losses in the IT, Healthcare, and Telecoms Services sectors.
India&#8217;s Nifty 50 was down 0.71% at 24,712.40, and the Nifty 500 slid 0.65% to 22,895.65.
China&#8217;s Shanghai Composite was down 0.75% at 3,377.00, and Shanghai Shenzhen CSI 300 fell 0.72% to 3,864.18.
Hong Kong&#8217;s Hang Seng closed the session 0.59% lower at 23,892.56.
Related: <a target="_blank" href="https://www.benzinga.com/markets/commodities/25/06/45897276/oil-etfs-surge-over-6-as-trump-orders-middle-east-evacuation-amid-iran-tensions-warns-region-could-be-dangerous" rel="noreferrer noopener">Oil ETFs Surge Over 6% As Trump Orders Middle East Evacuation Amid Iran Tensions, Warns Region &#8216;Could Be Dangerous&#8217;</a>
<h2 class="wp-block-heading">Eurozone at 05:45 AM ET</h2>
The European STOXX 50 index was down 1.33%.
Germany&#8217;s DAX index declined 1.35%.
France&#8217;s CAC 40 fell 1.03%.
U.K.&#8217;s FTSE 100 index traded lower by 0.38%.
<h2 class="wp-block-heading">Commodities</h2>
At 05:45 AM ET, the crude Oil WTI was trading higher by 7.54% at $73.17/bbl, and Brent was up 74.38% at $74.31/bbl.
Oil prices surged over 7% on Friday, hitting multi-month highs after Israel struck Iran&#8217;s nuclear sites, prompting retaliation and fears of supply disruption.
Natural gas rose 1.03% to $3.529.
Gold traded higher by 1.24% to $3,444.40, Silver rose 0.54% to $36.493, and Copper fell 1.90% to $4.7440.
<h2 class="wp-block-heading">US Futures</h2>
At 05:45 AM ET, Dow Jones futures were down 1.14%, the S&amp;P 500 declined 1.19%, and the Nasdaq 100 was down 1.48%.
U.S. stock futures fell after Israel&#8217;s strike on Iran raised Middle East tensions, spiking oil prices and boosting energy and defense stocks.
On Thursday, June 12, U.S. markets ended higher as optimism over artificial intelligence lifted investor sentiment. The S&amp;P 500 gained ground, led by a surge in Oracle shares after the company raised its outlook on strong AI-related demand. Gains in tech and gold mining stocks offset worries over Middle East tensions and a decline in Boeing shares. Softer inflation and labor data boosted hopes for an interest rate cut.
According to the economic data, U.S. producer prices rose 0.1% in May, below the 0.2% forecast, after a revised 0.2% drop in April. Initial jobless claims held at 248,000, above expectations of 240,000.
Most S&amp;P 500 sectors advanced Thursday, led by utilities, tech, and health care, while communication services and consumer discretionary lagged.
<h2 class="wp-block-heading">Forex</h2>
At 05:45 AM ET, the U.S. Dollar Index gained 0.45% to 98.31, USD/JPY was up 0.41% to 144.05, and USD/AUD rose 0.82% to 1.5430.
The dollar rallied Friday as investors sought safe havens after Israel&#8217;s strikes on Iran triggered retaliation.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/market-summary/25/06/45918802/middle-east-tensions-rattle-markets-us-stock-futures-slide-oil-jumps-8-gold-surges-above-3400-after-israel-strikes-iran" target="_blank" rel="noreferrer noopener">Middle East Tensions Rattle Markets: US Stock Futures Slide, Oil Jumps 8%, Gold Surges Above $3,400 After Israel Strikes Iran</a></li>
</ul>
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Global Markets Slide As Iran-Israel Conflict Heats Up, Oil Soars

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) with a Buy and maintains $75 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target

Cloudflare, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) on Friday <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45921345/cloudflare-inc-announces-pricing-of-offering-of-1-75-billion-of-0-convertible-senior-notes-due-203" rel="noreferrer noopener">announced the pricing</a> of $1.75 billion convertible senior notes due 2030 in a private offering by institutional buyers.
The company also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $250 million aggregate principal amount of the notes to cover over-allotments.
The notes&#8217; sale to the initial purchasers will likely settle on June 17, 2025, subject to customary closing conditions, resulting in $1.72 billion in net proceeds.
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44671105/cloudflare-acquires-outerbase-to-streamline-ai-app-development-our-goal-is-to-make-it-easy-and-accessible-for-any-developer" target="_blank" rel="noreferrer noopener">Cloudflare Acquires Outerbase To Streamline AI App Development, &#8216;Our Goal Is To Make It Easy And Accessible For Any Developer&#8217;</a>
Cloudflare may redeem the notes for cash if the last reported sale price of the stock has been at least 130% of the conversion price, which is then in effect for at least 20 trading days during any 30 consecutive trading day period.
The notes will be convertible at a premium of approximately 45% to the last reported sale price of $170.81 per share on June 12, 2025.
In connection with the pricing of the notes, Cloudflare entered into privately negotiated capped call transactions with certain of the initial purchasers and/or their respective affiliates and/or other financial institutions.
The cap price of the capped call transactions is approximately $469.73 per share, representing a premium of approximately 175% over the last reported sale price of $170.81.
Cloudflare intends to use approximately $248.0 million of the net proceeds to pay the cost of the capped call transactions. The remainder of the net proceeds from the offering will be used for general corporate purposes, which may include working capital, capital expenditures, repayment of outstanding indebtedness, and potential acquisitions and strategic transactions.
Cloudflare held $1.91 billion in cash and equivalents <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45303427/cloudflare-stock-rises-on-q1-earnings-after-landing-largest-contract-in-company-history-innovation-wins-in-a-constantly-changing-world" rel="noreferrer noopener">as of March 31, 2025</a>.
The company reported first-quarter revenue of&nbsp;$479.09 million, up 27% compared to&nbsp;estimates&nbsp;of $469.28 million. It reported adjusted EPS of&nbsp;16 cents compared to estimates of 17 cents.
Cloudflare expects second-quarter revenue of $500 million-$501 million versus estimates of $500.34 million. The company anticipates second-quarter adjusted earnings of 18 cents versus estimates of 19 cents.
Price Action: NET stock is trading lower by 2.78% to $166.06 premarket at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/45912952/oracles-ai-ambitions-take-flight-after-record-cloud-growth-what-do-analysts-really-think">Oracle&#8217;s AI Ambitions Take Flight After Record Cloud Growth: What Do Analysts Really Think?</a></li>
</ul>
Photo via Shutterstock

Offerings

Cloudflare To Raise $1.75 Billion In Note Offering For Expansion

Press Releases

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Legal

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Health Care

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Earnings

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

Management

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Akero Therapeutics

Alkermes

BridgeBio Pharma

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Metsera

Nuvalent

PTC Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Zai Lab Limited - American Depositary Shares

Zai Lab

Needham

Goldman Sachs

B of A Securities

Guggenheim

BTIG

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 모놀리식 파워 시스템즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>)의 주식은 24.68% 하락했다. 이는 엣지워터 리서치(Edgewater Research)의 분석 보고서에 따라 모놀리식의 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 블랙웰(Blackwell) GPU에 대한 할당이 전력 관리 IC의 성능 문제로 위험에 처해 있다고 밝힌 후 발생한 일이다.
2. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 24.23% 하락했다. 이는 회사가 최근  <a href="https://www.benzinga.com//node/41938588" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2024년 9월 30일 종료 분기 보고서를 제때</a> 제출할 수 없다고 발표한 후 주가가 급락했다.
3. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주식은 21.31% 하락했다. 이는 도널드 트럼프 대통령 당선인이 로버트 F. 케네디 주니어를 보건복지부(HHS) 장관으로 지명한 후 <a href="https://www.benzinga.com//node/42013119" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">백신 주식에 대한 압박</a>이 발생했기 때문이다.
4. 레이도스 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>)의 주식은 19.04% 하락했다. 이는 트럼프 대통령 당선인이 인수 기간 동안 연방 정부 주요직 임명을 했기 때문으로, 투자자들은 &#8220;<a href="https://www.benzinga.com//node/42013424" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">정부 효율성 부서</a>&#8220;에서의 가능한 삭감의 영향을 평가할 수 있다.
5. 먼데이닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)의 주식은 회사가 3분기 실적이 예상치를 웃돌고 연간 전망을 상향 조정했음에도 <a href="https://www.benzinga.com//node/41877454" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">불구하고</a> 지난주 18.94% 하락했다.
6. 백스사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>)의 주식은 18.60% 하락했다. 이는 도널드 트럼프 대통령 당선인이 로버트 F. 케네디 주니어를 HHS 장관으로 지명한 후 백신 주식에 대한 압박이 발생했기 때문이다.
7. 부즈 앨런 해밀턴 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>)의 주식은 18.59% 하락했다.
8. 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)의 주식은 17.30% 하락했다. 이는 2상 EMPOWER 시험이 <a href="https://www.benzinga.com/general/biotech/24/11/41881546/abbvie-9billion-schizophrenia-studies-bristol-myers-stock-surges" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주요 목표</a>를 달성하지 못했다고 발표한 후 발생한 일이다.
9. CACI 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>)의 주식은 17.16% 하락했다.
10. 샤오펑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>)의 주식은 16.89% 하락했다. 이는 미국에 상장된 중국 주식의 광범위한 하락세를 반영한 것이다. 이러한 시장 변화는 트럼프 당선인의 행정부 인사를 둘러싼 우려의 영향을 받을 수 있으며, 이는 <a href="https://www.benzinga.com//node/41946780" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">중국에 대한 더욱 강경한 입장</a>을 나타낼 수 있다.
또한 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%87%BC%ED%94%BC%ED%8C%8C%EC%9D%B4-%EB%94%94%EC%A6%88%EB%8B%88-%EB%B0%8F-%EC%BD%94%EC%9D%B8%EB%B2%A0%EC%9D%B4%EC%8A%A4%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC/" target="_blank" rel="noopener">쇼피파이, 디즈니 및 코인베이스는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 11일-15일)</a></li>
</ul>
이미지 출처: Robert Way via Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Vaxcyte

뉴스

에 대한 최신 뉴스 Vaxcyte (NASDAQ:PCVX) 주식

일요일, 11월 17, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌